According to a Bloomberg article, Dr. Reddy’s Laboratories Ltd., India’s second-biggest drugmaker by revenue, will invest about $320 million over the next four years to develop its portfolio of biologic and proprietary medicines, Chief Operating Officer Abhijit Mukherjee said. Dr. Reddy’s, which gets 80 percent of sales from generic drugs, plans to seek permission to sell two proprietary medicines in the U.S. within the next year, Mukherjee said in a June 17 interview. The company also obtained approval from the FDA to start clinical trials for two biosimilars. Read the full story